Technology: AdvaTab®
AdvaTab orally disintegrating tablets (ODT) use Eurand’s proprietary granulation and tableting processes to produce a formulation that rapidly disintegrates on contact with saliva. AdvaTab tablets are designed to meet FDA guidance regarding ODTs, including a disintegration time of 15 to 30 seconds without the need to chew or drink liquid.
The tablets are created using polymer-coated drug particles that are uniformly dispersed in an ultra-fine, low-water content, rapidly disintegrating matrix with superior organoleptic properties. AdvaTab tablets are compressed using a proprietary, patented, external lubrication system in which the lubricant is applied only to the tablet surface, resulting in robust tablets that are hard and less friable and can be packaged in bottles or blisters.
The AdvaTab technology has the flexibility to be combined with Eurand’s proprietary Microcaps taste-masking and/or Diffucaps customized drug release technologies to create tablets with high dose capacity, customized release profiles, and a pleasant taste and mouth feel. Together, these technologies may enhance compliance by providing patients with a convenient, easy-to-swallow product with a pleasant taste.
Advantages of AdvaTab
- Robust tablets, suitable for bottles or blister packs
- Combine with Microcaps technology for pleasant taste and mouth feel
- Combine with Diffucaps technology for custom release profiles
- Multiple technologies can be combined in one product
- Protected by issued and pending U.S. and international patents
Positive Patient Experience1,2
Patient convenience and satisfaction with AdvaTab ODT were measured in a study of 97 patients who switched from an immediate release formulation to a formulation using AdvaTab technology.
- Patients found AdvaTab to be significantly more convenient than the reference product (P<0.001)
- Patients were more likely to take AdvaTab ODT as prescribed (missing fewer doses) compared with the immediate-release formulation (P<0.001)
AdvaTab ODT technology can be combined with Microcaps taste-masking and/or Diffucaps customized release profile technologies.
1.Nanry K, et al. Epilepsia. 2008;49(S7):Abstract 1.237.